Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs enGene Therapeutics Inc (ENGN)

Coherus Oncology, Inc. and enGene Therapeutics Inc are both Biotechnology companies. Coherus Oncology, Inc. and enGene Therapeutics Inc are of similar size ($115.7M and $112.6M). enGene Therapeutics Inc has the higher net margin (0.00% vs −259.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, enGene Therapeutics Inc leads on 9 and Coherus Oncology, Inc. on 4.

Valuation

Metric CHRS ENGN Biotechnology median
P/E n/m n/m 10.60
P/S 2.34 n/m 9.40
P/B 1.96 0.53 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.86 0.66
EV/Sales 4.44 n/m 9.02
Earnings yield (133.77%) (117.61%) (32.88%)
Free cash flow yield (156.84%) (84.73%) (23.13%)

Profitability

Metric CHRS ENGN Biotechnology median
Gross margin 68.94% — 68.51%
Operating margin (311.56%) 0.00% 0.00%
Net margin (259.41%) 0.00% 0.00%
Free cash flow margin (365.22%) 0.00% 0.00%
Return on equity (146.27%) (60.50%) (51.96%)
Return on assets (41.90%) (48.84%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS ENGN Biotechnology median
Revenue growth (TTM) 61.00% — 6.76%
EPS growth (last fiscal year) 472.00% (56.85%) 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS ENGN Biotechnology median
Debt to equity 0.61 0.11 0.00
Current ratio 1.77 10.21 4.97
Net debt to EBITDA 0.76 1.42 1.01

Dividend

Metric CHRS ENGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CHRS ENGN Biotechnology median
Market cap 115.71m 112.59m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack